EP1303287A1 - In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung - Google Patents
In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendungInfo
- Publication number
- EP1303287A1 EP1303287A1 EP01942207A EP01942207A EP1303287A1 EP 1303287 A1 EP1303287 A1 EP 1303287A1 EP 01942207 A EP01942207 A EP 01942207A EP 01942207 A EP01942207 A EP 01942207A EP 1303287 A1 EP1303287 A1 EP 1303287A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- peptides
- immunogen
- amino acid
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 337
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 231
- 238000000034 method Methods 0.000 title claims abstract description 65
- 206010060862 Prostate cancer Diseases 0.000 title claims abstract description 22
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 69
- 201000011510 cancer Diseases 0.000 claims abstract description 41
- 230000004044 response Effects 0.000 claims abstract description 40
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 33
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 33
- 239000002157 polynucleotide Substances 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 26
- 201000001514 prostate carcinoma Diseases 0.000 claims abstract description 9
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 109
- 229920001184 polypeptide Polymers 0.000 claims description 90
- 108090000623 proteins and genes Proteins 0.000 claims description 89
- 230000002163 immunogen Effects 0.000 claims description 80
- 102000004169 proteins and genes Human genes 0.000 claims description 69
- 150000001413 amino acids Chemical class 0.000 claims description 56
- 108010038807 Oligopeptides Proteins 0.000 claims description 30
- 102000015636 Oligopeptides Human genes 0.000 claims description 30
- 210000004881 tumor cell Anatomy 0.000 claims description 27
- 230000008569 process Effects 0.000 claims description 25
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 230000014509 gene expression Effects 0.000 claims description 21
- 238000000338 in vitro Methods 0.000 claims description 20
- 102000004127 Cytokines Human genes 0.000 claims description 18
- 108090000695 Cytokines Proteins 0.000 claims description 18
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 18
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 18
- 239000013598 vector Substances 0.000 claims description 17
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 229960005486 vaccine Drugs 0.000 claims description 15
- 230000001939 inductive effect Effects 0.000 claims description 13
- 239000002243 precursor Substances 0.000 claims description 10
- 230000009089 cytolysis Effects 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 230000006378 damage Effects 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 230000022120 response to tumor cell Effects 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 22
- 230000002265 prevention Effects 0.000 abstract description 5
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 85
- 235000018102 proteins Nutrition 0.000 description 68
- 235000001014 amino acid Nutrition 0.000 description 52
- 229940024606 amino acid Drugs 0.000 description 49
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 41
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 41
- 210000000612 antigen-presenting cell Anatomy 0.000 description 21
- 239000012634 fragment Substances 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 18
- 210000001744 T-lymphocyte Anatomy 0.000 description 16
- 125000000539 amino acid group Chemical class 0.000 description 13
- 230000028993 immune response Effects 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 238000013459 approach Methods 0.000 description 12
- 201000010099 disease Diseases 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 12
- 108091026890 Coding region Proteins 0.000 description 9
- 230000000890 antigenic effect Effects 0.000 description 9
- 210000004443 dendritic cell Anatomy 0.000 description 9
- 239000003937 drug carrier Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 238000001727 in vivo Methods 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 230000027455 binding Effects 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 108091008874 T cell receptors Proteins 0.000 description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000002068 genetic effect Effects 0.000 description 6
- 210000000987 immune system Anatomy 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 230000004936 stimulating effect Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 108010002350 Interleukin-2 Proteins 0.000 description 5
- 102000043129 MHC class I family Human genes 0.000 description 5
- 108091054437 MHC class I family Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- -1 clones Substances 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 125000006850 spacer group Chemical group 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 3
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 3
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 206010033128 Ovarian cancer Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- 210000000805 cytoplasm Anatomy 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 125000001151 peptidyl group Chemical group 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 108091016585 CD44 antigen Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 150000008574 D-amino acids Chemical class 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 102100028765 Heat shock 70 kDa protein 4 Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002586 Interleukin-7 Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 150000008575 L-amino acids Chemical class 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 239000013599 cloning vector Substances 0.000 description 2
- 201000010989 colorectal carcinoma Diseases 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 201000005296 lung carcinoma Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- IYKLZBIWFXPUCS-VIFPVBQESA-N (2s)-2-(naphthalen-1-ylamino)propanoic acid Chemical compound C1=CC=C2C(N[C@@H](C)C(O)=O)=CC=CC2=C1 IYKLZBIWFXPUCS-VIFPVBQESA-N 0.000 description 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000009333 Apolipoprotein D Human genes 0.000 description 1
- 108010025614 Apolipoproteins D Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108090000018 Carboxypeptidase D Proteins 0.000 description 1
- 102100032407 Carboxypeptidase D Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- 229930182847 D-glutamic acid Natural products 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 102100034165 E3 ubiquitin-protein ligase RNF13 Human genes 0.000 description 1
- 101710109051 E3 ubiquitin-protein ligase RNF13 Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 208000000666 Fowlpox Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 102100028972 HLA class I histocompatibility antigen, A alpha chain Human genes 0.000 description 1
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 description 1
- 102100028971 HLA class I histocompatibility antigen, C alpha chain Human genes 0.000 description 1
- 108010075704 HLA-A Antigens Proteins 0.000 description 1
- 108010058607 HLA-B Antigens Proteins 0.000 description 1
- 108010052199 HLA-C Antigens Proteins 0.000 description 1
- 101710089244 Heat shock 70 kDa protein 4 Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100025190 Histone-binding protein RBBP4 Human genes 0.000 description 1
- 101710181537 Histone-binding protein RBBP4 Proteins 0.000 description 1
- 102100023584 Histone-binding protein RBBP7 Human genes 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001078692 Homo sapiens Heat shock 70 kDa protein 4 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102100030130 Interferon regulatory factor 6 Human genes 0.000 description 1
- 101710157822 Interferon regulatory factor 6 Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 101710177504 Kit ligand Proteins 0.000 description 1
- 125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100035386 NADH dehydrogenase [ubiquinone] 1 subunit C2 Human genes 0.000 description 1
- 101710162998 NADH dehydrogenase [ubiquinone] 1 subunit C2 Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 230000004570 RNA-binding Effects 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108700005078 Synthetic Genes Proteins 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 108010033576 Transferrin Receptors Proteins 0.000 description 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- DIZPMCHEQGEION-UHFFFAOYSA-H aluminium sulfate (anhydrous) Chemical compound [Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O DIZPMCHEQGEION-UHFFFAOYSA-H 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 230000005859 cell recognition Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 108010004073 cysteinylcysteine Proteins 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940124466 diagnostic for cancer Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 108010030457 histone acetyltransferase type B complex Proteins 0.000 description 1
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
- 238000012872 hydroxylapatite chromatography Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000001024 immunotherapeutic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000013546 insoluble monolayer Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000002889 oleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000006069 physical mixture Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008884 pinocytosis Effects 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000030788 protein refolding Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 231100000628 reference dose Toxicity 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 102000003702 retinoic acid receptors Human genes 0.000 description 1
- 108090000064 retinoic acid receptors Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 108010087967 type I signal peptidase Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates generally to the field of immunogens and peptide expression in cancerous cells of the prostate and to processes of using such peptides and their over-expression for the development of vaccines and as therapeutic agents for stimulation of the immune system for the purpose of killing prostate cancer cells, such as in eliciting cytotoxic T lymphocyte (CTL) responses for the diagnosis, prevention and treatment of cancer.
- CTL cytotoxic T lymphocyte
- T cells The mammalian immune system has evolved a variety of mechanisms to protect the host from cancerous cells, an important component of this response being mediated by cells referred to as T cells.
- Cytotoxic T lymphocytes CTLs
- CTLs Cytotoxic T lymphocytes
- cytokines soluble molecules
- Evidence suggests that immunotherapy designed to stimulate a tumor-specific CTL response would be effective in controlling cancer. For example, it has been shown that human CTLs recognize sarcomas (Slovin, S. F.
- MHC- peptide complex which is located on the surface of the cancerous cell.
- MHC major histocompatibility-complex
- HLA human leukocyte antigens
- the peptides that associate with the MHC molecules can either be derived from proteins made within the cell, in which case they typically associate with class I MHC molecules (Rock, K. L. and Golde, U., Ann.Rev.lmmunol., 17:739-779, (1999)) or they can be derived from proteins that are acquired from outside of the cell, in which case they typically associate with class II MHC molecules (Watts, C, Ann.Rev.lmmunol., 15:821 -850, (1997)). Peptides that evoke a cancer- specific CTL response most typically associate with class I MHC molecules.
- the peptides that associate with a class I MHC molecule are typically nine amino acids in length, but can vary from a minimum length of eight amino acids to a maximum of fourteen amino acids in length.
- a class I MHC molecule with its bound peptide, or a class II MHC molecule with its bound peptide, is referred to as an MHC-peptide complex.
- antigen processing The process by which intact proteins are degraded into peptides is referred to as antigen processing.
- Two major pathways of antigen processing occur within cells (Rock, K. L. and Golde, U., Ann.Rev.lmmunol. , 17:739-779, (1999); Watts, C, Ann.Rev.lmmunol., 15:821-850, (1997)).
- One pathway which is largely restricted to cells that are antigen presenting cells such as dendritic cells, macrophages, and B cells, degrades proteins that are typically phagocytosed or endocytosed into the cell. Peptides derived in this pathway typically bind to class II MHC molecules.
- a second pathway of antigen processing is present in essentially all cells of the body.
- This second pathway primarily degrades proteins that are made within the cells, and the peptides derived from this pathway primarily bind to class I MHC molecules.
- Antigen processing by this latter pathway involves polypeptide synthesis and proteolysis in the cytoplasm.
- the peptides produced are then transported into the endoplasmic reticulum of the cell, associate with newly synthesized class I MHC molecules, and the resulting MHC-peptide complexes are then transported to the cell surface.
- Peptides derived from membrane and secreted proteins have also been identified. In some cases these peptides correspond to the signal sequence of the proteins that are cleaved from the protein by the signal peptidase. In other cases, it is thought that some fraction of the membrane and secreted proteins are transported from the endoplasmic reticulum into the cytoplasm where processing subsequently occurs.
- the peptides are recognized by antigen-specific receptors on CTLs. Mere expression of the MHC molecule itself is insufficient to trigger the CTL to kill the target cell if the antigenic peptide is not bound to the MHC molecule.
- CTLs Several methods have been developed to identify the peptides recognized by CTL, each method relying on the ability of a CTL to recognize and kill only those cells expressing the appropriate MHC molecule with the peptide bound to it (Rosenberg, S. A., Immunity, 10:281-287, (1999)).
- Such peptides can be derived from a non-self source, such as a pathogen (for example, following the infection of a cell by a bacterium or a virus) or from a self-derived protein within a cell, such as a cancerous cell.
- a pathogen for example, following the infection of a cell by a bacterium or a virus
- a self-derived protein within a cell such as a cancerous cell.
- Immunity 10:281 -287, (1999) and include: (i) mutated genes; (ii) aberrantly expressed genes such as an alternative open reading frame or through an intron-exon boundary; (iii) normal genes that are selectively expressed in only the tumor and the testis; and (iv) normal differentiation genes that are expressed in the tumor and the normal cellular counterpart.
- mutated genes such as an alternative open reading frame or through an intron-exon boundary
- normal genes that are selectively expressed in only the tumor and the testis
- normal differentiation genes that are expressed in the tumor and the normal cellular counterpart.
- Four different methodologies have typically been used for identifying the peptides that are recognized by CTLs. These are: (i) the genetic method;
- SErological analysis of REcombinant cDNA expression libraries SErological analysis of REcombinant cDNA expression libraries
- DIRECTTM Direct Identification of Relevant Epitopes for Clinical Therapeutics
- the genetic method is an approach in which progressively smaller subsets of cDNA libraries from tumor cells are transfected into cells that express the appropriate MHC molecule but not the tumor-specific epitope.
- the molecular clones encoding T cell epitopes are identified by their ability to reconstitute tumor specific T cell recognition of transfected cells.
- the exact T cell epitope is then identified by a combination of molecular subcloning and the use of synthetic peptides based on the predicted amino acid sequence.
- Such methods are susceptible to inadvertent identification of cross-reacting peptides, and are not capable of identifying important post-translational modifications.
- Motif analysis involves scanning a protein for peptides containing known class I MHC binding motifs, followed by synthesis and assay of the predicted peptides for their ability to be recognized by tumor-specific CTL. This approach requires prior knowledge of the protein from which the peptides are derived. This approach is also greatly hampered by the fact that not all of the predicted peptide epitopes are presented on the surface of a cell (Yewdell, J. W. and Bennink, J. R., Ann.Rev.lmmunol., 17:51-88, (1999)), thus additional experimentation is required to determine which of the predicted epitopes is useful.
- the SEREXTM approach relies on using antibodies in the serum of cancer patients to screen cDNA expression libraries for a clone that expresses a protein recognized by the antibody. This methodology presumes that an antibody response will necessarily have developed in the presence of a T cell response, and thus, the identified clone is a good candidate to encode a protein that can be recognized by T cells.
- DIRECTTM involves a combination of cellular immunology and mass spectrometry.
- This approach involves the actual identification of CTL epitopes by sequencing the naturally occurring peptides associated with MHC molecules.
- cells are first lysed in a detergent solution, the peptides associated with the MHC molecules are purified, and the peptides fractionated by high performance liquid chromatography (HPLC). The peptides are then used to reconstitute recognition by tumor- specific CTLs on a non-tumor cell expressing the appropriate MHC molecules. Sequencing is readily performed by tandem mass spectrometry (Henderson, R. A.
- Immunization with cancer-derived, MHC-encoded molecule- associated peptides, or with a precursor polypeptide or protein that contains the peptide, or with a gene that encodes a polypeptide or protein containing the peptide, are forms of immunotherapy that can be employed in the treatment of cancer. These forms of immunotherapy require that immunogens be identified so that they can be formulated into an appropriate vaccine. Although a variety of cancer-derived antigens have been identified (Rosenberg, S. A., Immunity, 10:281 -287, (1999)), not all of these are appropriate for broad-based immunotherapy as the expression of some peptides is limited to the tumor derived from a specific patient.
- MHC molecules from which tumor-derived peptides have been discovered is largely restricted to HLA-A2.
- Such peptides would be particularly useful in the treatment of cancer patients who do not express the HLA-A2 molecule.
- antigenic peptides that are derived from different parent proteins Because an active immune response can result in the outgrowth of tumor cells that have lost the expression of a particular precursor protein for a given antigenic peptide, it is advantageous to stimulate an immune response against peptides derived from more than one parent protein since the chances of the tumor cell losing the expression of both proteins is the multiple of the chances of losing each of the individual proteins.
- class I and class II MHC peptides have been identified that are over expressed on prostate cancer cells.
- the amino acid sequences of these peptides is provided.
- the present invention relates to immunogens, such as immunogenic polypeptides, comprising within their sequences the one or more of the immunogenic peptides disclosed herein, such peptides including amino acid sequences comprising epitopic sequences selected from the sequences of SEQ ID NO: 1 - 31 and which immunogens facilitate a cytotoxic T lymphocyte (CTL)-mediated immune response against cancers.
- immunogens such as immunogenic polypeptides
- immunogens including amino acid sequences comprising epitopic sequences selected from the sequences of SEQ ID NO: 1 - 31 and which immunogens facilitate a cytotoxic T lymphocyte (CTL)-mediated immune response against cancers.
- CTL cytotoxic T lymphocyte
- the present invention also relates to nucleic acid molecules that encode for the polypeptides, and/or the full length proteins from which the polypeptides are derived, of such immunogens, and which can also be used to facilitate an immune response against cancer.
- compositions comprising the immunogen described herein, and polynucleotides that direct the synthesis of such polypeptides, whereby the oligopeptides and polypeptides of such immunogens are capable of inducing a CTL response against cells expressing a protein comprising an epitopic sequence of SEQ ID NO: 1 - 31 presented in association with MHC class I or II molecules.
- the cells are usually cancer cells, especially prostate cancer cells, expressing such proteins.
- the present invention further relates to proteins containing the peptide sequences disclosed herein.
- the present invention further relates to polynucleotides comprising the gene coding for a polypeptide of the immunogens disclosed herein.
- the present invention also provides vaccines comprising the immunogenic peptides disclosed herein, such as where said peptides are part of the immunogens of the invention, and wherein said vaccines are useful in stimulating the immune system of a recipient against cancerous cells, especially cancer of the prostate.
- the present invention also provides methods that comprise contacting a lymphocyte, especially a CTL, with an immunogen of the invention under conditions that induce a CTL response against a tumor cell, and more specifically against a cancer cell.
- the methods may involve contacting the CTL with the immunogenic peptide in vivo, in which case the peptides, polypeptides, and polynucleotides of the invention are used as vaccines, and will be delivered as a pharmaceutical composition comprising a pharmaceutically acceptable carrier and the immunogen, typically along with an adjuvant or one or more cytokines.
- the immunogens of the present invention can be used to induce a CTL response in vitro.
- the generated CTL can then be introduced into a patient with cancer, more specifically cancer, colorectal carcinoma, ovarian carcinoma, lung carcinoma, or prostate carcinoma.
- the ability to generate CTL in vitro can serve as a diagnostic for cancer, colorectal carcinoma, ovarian carcinoma, lung carcinoma, or prostate carcinoma.
- peptide is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids.
- the peptides are typically 9 to 18 amino acids in length, but can be as short as 3 amino acids in length, and as long as 20 amino acids in length.
- oligopeptide is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids.
- the length of the oligopeptide is not critical to the invention as long as the correct epitope or epitopes are maintained.
- the oligopeptides are typically less than about 30 amino acid residues in length, and greater than about 14 amino acids in length.
- polypeptide designates a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha- amino and carbonyl groups of the adjacent amino acids.
- the length of the polypeptide is not critical to the invention as long as the correct epitopes are maintained.
- polypeptide is meant to refer to protein molecules of longer than about 30 residues in length.
- a peptide, oligopeptide, protein, or polynucleotide coding for such a molecule is "immunogenic” (and thus an "immunogen" within the present invention) if it is capable of inducing an immune response.
- immunogenicity is more specifically defined as the ability to induce a CTL-mediated response.
- an "immunogen” would be a molecule that is capable of inducing an immune response, and in the case of the present invention, a molecule capable of inducing a CTL response.
- a T cell "epitope” is a short peptide molecule that binds to a class I or II MHC molecule and that is subsequently recognized by a T cell.
- T cell epitopes that bind to class I MHC molecules are typically 8-14 amino acids in length, and most typically 9 amino acids in length.
- T cell epitopes that bind to class II MHC molecules are typically 12-20 amino acids in length.
- the same T cell epitope may share a common core segment, but differ in the length of the carboxy- and amino- terminal flanking sequences due to the fact that ends of the peptide molecule are not buried in the structure of the class II MHC molecule peptide-binding cleft as they are in the class I MHC molecule peptide-binding cleft.
- coding region refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene.
- the coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.
- nucleotide sequence refers to a heteropolymer of deoxyribonucleotides.
- the nucleotide sequence encoding for a particular peptide, oligopeptide, or polypeptide may be naturally occurring or they may be synthetically constructed.
- DNA segments encoding the peptides, polypeptides, and proteins of this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene which is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.
- expression product means that polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).
- fragment when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.
- DNA segment refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, by using a cloning vector.
- segments are provided in the form of an open reading frame uninterrupted by internal nontranslated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.
- primer means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.
- promoter means a region of DNA involved in binding of RNA polymerase to initiate transcription.
- ORF open reading frame
- isolated means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring).
- a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated.
- Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.
- polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in "purified” form.
- the term “purified” does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art.
- individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated.
- the claimed polypeptide which has a purity of preferably 0.001 %, or at least 0.01 % or 0.1 %; and even desirably 1 % by weight or greater is expressly contemplated.
- nucleic acids and polypeptide expression products disclosed according to the present invention may be in "enriched form.”
- enriched means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01 %, by weight, preferably at least about 0.1 % by weight. Enriched preparations of about 0.5%, 1 %, 5%, 10%, and 20% by weight are also contemplated.
- sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.
- active fragment means a fragment that generates an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant, to an animal, such as a mammal, for example, a rabbit or a mouse, and also including a human, such immune response taking the form of stimulating a CTL response within the recipient animal, such as a human.
- an animal such as a mammal, for example, a rabbit or a mouse
- the "active fragment” may also be used to induce a CTL response in vitro.
- portion when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence.
- the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. This means that any such fragment will necessarily contain as part of its amino acid sequence a segment, fragment or portion, that is substantially identical, if not exactly identical, to a sequence of SEQ ID NOs: 1-31.
- polynucleotides such terms refer to the products produced by treatment of said polynucleotides with any of the common endonucleases.
- the term "percent identity” or “percent identical,” when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the “Reference Sequence”).
- the Percent Identity is then determined according to the following formula:
- C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the
- the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the herein above calculated Percent Identity is less than the specified Percent Identity.
- Peptide or polypeptide mimetics include peptides or polypeptides having one or more of the following modifications:
- a non-peptidyl linkage such as a --CH2- carbamate linkage (-CH2OC(O)NR ⁇ ), a phosphonate linkage, a -CH2- sulfonamide (-CH 2 » S(O)2NR--) linkage, a urea (-NHC(O)
- sequences wherein the N-terminus is derivatized to a -NRR1 group, to a - NRC(O)R group, to a -NRC(O)OR group, to a -NRS(O)2R group, to a -NHC(O)NHR group where R and R1 are hydrogen or C1-C4 alkyl with the proviso that R and R1 are not both hydrogen;
- Naturally occurring amino acid residues in peptides/polypeptides are abbreviated as recommended by the IUPAC-IUB Biochemical Nomenclature Commission as follows: Phenylalanine is Phe or F; Leucine is Leu or L; Isoleucine is He or I; Methionine is Met or M; Norleucine is Nle; Valine is Vat or V; Serine is Ser or S; Proline is Pro or P; Threonine is Thr or T; Alanine is Ala or A; Tyrosine is Tyr or Y; Histidine is His or H; Glutamine is Gin or Q Asparagine is Ash or N; Lysine is Lys or K; Aspartic Acid is Asp or D Glutamic Acid is Glu or E; Cysteine is Cys or C; Tryptophan is Trp or W Arginine is Arg or R; Glycine is Gly or G, and X is any amino acid.
- Other naturally occurring amino acids include, by way of example, 4-hydroxyproline
- Synthetic or non-naturally occurring amino acids refer to amino acids which do not naturally occur in vivo but which, nevertheless, can be incorporated into the peptide/polypeptide structures described herein.
- the resulting "synthetic peptide" contain amino acids other than the 20 naturally occurring, genetically encoded amino acids at one, two, or more positions of the peptides. For instance, naphthylalanine can be substituted for trytophan to facilitate synthesis.
- Other synthetic amino acids that can be substituted into peptides include L-hydroxypropyl, L-3,4-dihydroxyphenylalanyl, alpha- amino acids such as L-alpha-hydroxylysyl and D-alpha-methylalanyl, L-alpha.- methylalanyl, beta.-amino acids, and isoquinolyl.
- D amino acids and non- naturally occurring synthetic amino acids can also be incorporated into the peptides.
- Other derivatives include replacement of the naturally occurring side chains of the 20 genetically encoded amino acids (or any L or D amino acid) with other side chains.
- the term "pharmaceutically acceptable carrier” encompasses any of the standard pharmaceutical carriers, such as a phosphate buffered saline solution, water and emulsions such as an oil/water or water/oil emulsion, and various types of wetting agents, all as disclosed below.
- the present invention relates to immunogenic peptides, including four class I MHC peptides (SEQ ID NO: 1 - 4) and ten class II MHC peptides, along with their respective nested sets, (SEQ ID NO: 5 - 31), which find use as vaccines or therapeutics to stimulate the immune system to kill prostate cancer cells. Proteins containing the above peptide sequences have also been identified and could also be employed to either stimulate an immune response against the cancer or function as diagnostic markers of the disease.
- oligopeptide sequences with amino acid sequences shown in SEQ ID NO: 1 to 31 which represent epitopic peptides (i.e. immunogenic oligopeptide sequences) of at least about 8 amino acids in length, preferably about 9 to 16 amino acids in length, and no longer than about 20 amino acids in length and present as part of a larger structure, such as a polypeptide or full length protein.
- epitopic peptides i.e. immunogenic oligopeptide sequences
- Proteins already known as immunogens in the art, and which comprise one or more of the peptides disclosed herein, are specifically excluded from the present invention.
- polypeptides forming the immunogens of the present invention have amino acid sequences that comprise at least one stretch, possibly two, three, four, or more stretches of about 8 to 18 residues in length and which stretches differ in amino acid sequence from the sequences of SEQ ID NO: 1 -31 by no more than about 1 to 3, possibly more, amino acid residues, preferably a conservative amino acid residue, especially amino acids of the same general chemical character, such as where they are hydrophobic amino acids.
- Said polypeptides can be of any desired length so long as they have immunogenic activity in that they are able, under a given set of desirable conditions, to elicit in vitro or in vivo the activation of cytotoxic T lymphocytes (CTLs) (i.e., a CTL response) against a presentation of a cancer specific protein, especially a prostate cancer specific protein, most especially the proteins disclosed herein as comprising the immunogenic or epitopic peptides disclosed according to the invention, especially when such proteins are presented along with MHC-1 or MHC-2 proteins, as the case may be, such as where said proteins are presented in vitro or in vivo by an antigen presenting cell (APC).
- CTLs cytotoxic T lymphocytes
- APC antigen presenting cell
- the proteins and polypeptides forming the immunogens of the present invention can be naturally occurring or may be synthesized chemically.
- the present invention is also directed to an isolated polypeptide, especially one having immunogenic activity, the sequence of which comprises within it one or more stretches comprising any 2 or more of the sequences of SEQ ID NO: 1 -31 and in any relative quantities and wherein said sequences may differ by one or several amino acid residues from the sequences of SEQ ID NO: 1 -31 in any given stretch of 8 to 10 amino acid residues for the MHC class I related sequences and 15 to 19 amino acid residues for the class II related sequences.
- such a polypeptide may contain as part of its amino acid sequence, fragments having up to 8 amino acids identical to a sequence of SEQ ID NO: 1 -4 such that the polypeptide comprises, in a specific embodiment, 2 segments with at least 8 residues identical to SEQ ID NO: 1 and 1 segment with at least 8 residues identical to SEQ ID NO: 3, or a stretch of at least 15 contiguous residues drawn from SEQ ID NO: 5 - 31 , such that the polypeptide comprises, in a specific and non-limiting embodiment, 2 segments with at least 15 residues identical to SEQ ID NO: 5 and 1 segment with at least 15 residues identical to SEQ ID NO: 9.
- a polypeptide of the present invention may comprise 2 copies of the sequence of SEQ ID NO: 2 at some point or points within its length.
- any combinations and permutations of the epitopes disclosed herein, as long as they are present at least two in number in such polypeptides, are expressly contemplated.
- epitopic peptides of the invention are ultimately derived from proteins expressed by cancer cells and sequences were identified through the method of Automated High Through-put Sequencing (HTPS).
- HTPS Automated High Through-put Sequencing
- the first of the peptides has the sequence, YEKILFTEA (SEQ ID NO: 1), and is derived from the 26S Proteasome Regulatory Subunit SI4 protein (residues 186 to 194 inclusive).
- the second peptide has the sequence, TYGEIFEKF (SEQ ID NO: 2), and is derived from the NADH-ubiquinone oxidoreductase subunit B14.5B protein (residues 107 to 115 inclusive ).
- the third peptide has the sequence, GEFGGFGSV (SEQ ID NO: 3), which is found in both the Chromatin assembly factor I P48 subunit protein (residues 103 to III inclusive) and the Histone acetyltransferase type B subunit 2 protein (residues 102 to 110 inclusive).
- the fourth peptide has the sequence, MTDLDIKFQY (SEQ ID NO: 4), and is derived from the Interferon regulatory factor 6 protein (residues 223 to 232 inclusive).
- the peptides were isolated from prostate cancer cells using the following procedure. Briefly, two cell lines from the same patient, one from prostate cancer cells and the other from healthy prostate tissue, were grown in culture. MHC Class I peptides were immunoaffinity purified with W6/32 antibody from both cell lines. An aliquot of each sample was loaded on a reverse-phase (C18) micro-capillary column and gradient eluted directly into a Fourier transform mass spectrometer. Mass spectra were obtained at a rate of approximately one per second, resulting in a total of roughly 1000 mass spectra per sample.
- each 25 consecutive mass spectra of class I peptides from the prostate cancer sample were summed, a peak list was generated and compared to the peak list resulting from the corresponding sum of 25 scans recorded on class I peptides isolated from healthy prostate cells.
- Signals present in the sample from prostate cancer but absent in the normal prostate sample were marked. Further analysis allowed for quantification of the differences for these marked species. Those species that differed by a factor of 9 or more (greater in the cancerous prostate sample by at least a factor of 9) were placed in a candidate list. Species on the candidate list were identified through fragmentation (collision-activated dissociation) on the LCQ ion trap mass spectrometer followed by manual sequencing and database searching.
- the present invention also encompasses any amino acid sequence comprising a peptide sequence selected from the group consisting of YEKILFTEA (SEQ ID NO: 1), TYGEIFEKF (SEQ ID NO: 2), GEFGGFGSV (SEQ ID NO: 3) and MTDLDIKFQY (SEQ ID NO: 4), or a peptide identical to one of those four peptides but differing by one, two or three conservative amino acid substitutions.
- the invention also encompasses peptide mimetics of the peptides YEKILFTEA (SEQ ID NO: 1), TYGEIFEKF (SEQ ID NO: 2), GEFGGFGSV (SEQ ID NO: 3) and MTDLDIKFQY (SEQ ID NO: 4). They too could be employed to either stimulate an immune response against the cancer or function as diagnostic markers of the disease.
- the present invention also relates to 10 class II MHC peptides, including the following.
- the first of the ten peptides has the sequence, GERAMTKDNNLLGKFELT (SEQ ID NO: 5), and is derived from Heat Shock 70kD Protein 10 (HSC71) (residues 445 to 462 inclusive).
- the nested set contains the following sequences, EGERAMTKDNNLLGKFE (SEQ ID NO: 6), GERAMTKDNNLLGK (SEQ ID NO: 7), ERAMTKDNNLLGKFE (SEQ ID NO: 8).
- the second peptide has the sequence, VPGTYKITASARGYNP (SEQ ID NO: 1
- VPGTYKITASARGYNPV (SEQ ID NO: 10)
- PGTYKITASARGYNP (SEQ ID NO: 10)
- the third peptide has the sequence, LNQELRADGTVNQIEG (SEQ ID NO: 12), and is derived from the Apolipoprotein D Protein (residues 57 to 72 inclusive).
- the nested set contains the following sequences,
- the fourth peptide has the sequence, TGQFLYQDSNWASK (SEQ ID NO: 1
- the nested set contains the following sequence, TGQFLYQDSNWASKVE (SEQ ID NO: 17).
- the fifth peptide has the sequence, NPLEIVSIPDNHGHID (SEQ ID NO: 18), and is derived from the Retinoic Acid Receptor Responder Protein (residues 170 to 185 inclusive ).
- the sixth peptide has the sequence, DLPEYQGEPDEISIQK (SEQ ID NO: 1
- the nested set contains the following sequences, LPEYQGEPDEISIQK (SEQ ID NO: 20),
- IDLPEYQGEPDEISIQK (SEQ ID NO: 21).
- the seventh peptide has the sequence, IPSVFIGESSANSLKDE (SEQ ID NO: 22), and is derived from the Ring Finger Protein 13 (residues 145 to 161 inclusive).
- the nested set contains the following sequence, IPSVFIGESSANSLK (SEQ ID NO: 23).
- the eighth peptide has the sequence, KQSLTMDPWKSKEIE (SEQ ID NO: 24), and is derived from the Heat Shock 70kD Protein 4 (Heat Shock 70- related protein APG-2) (residues 754 to 769 inclusive).
- the nested set contains the following sequences, NKQSLTMDPVVKSKEIE (SEQ ID NO: 25), NKQSLTMDPWKSKEIEA (SEQ ID NO: 26), KQSLTMDPWKSKE (SEQ ID NO: 27).
- the ninth peptide has the sequence, GRYSISRTEAADLC (SEQ ID NO: 28), wherein the C-terminal C is a cysteinyl-derivative (representing a cysteinyl-cysteine) and is derived from the CD44 Antigen Precursor Protein (phagocytic glycoprotein I) (residues 40 to 53 inclusive).
- the nested set contains the following sequences, NGRYSISRTEAADLC (SEQ ID NO: 29), KNGRYSISRTEAADLC (SEQ ID NO: 30) (and wherein the C-terminal C of both SEQ ID NO: 29 and 30 represent cysteinylated cysteine).
- the tenth peptide has the sequence, DPSYVNVQNLDKARQ (SEQ ID NO: 31), and is derived from the SHC Transforming Protein (p66shc) (residues 424 to 438 inclusive).
- the peptides were isolated from prostate cancer cells using a procedure substantially similar to that recited above except for the use of MHC Class II peptides in place of class I.
- the initial immunoaffinity step utilized LB3.1 (pan DR) antibody in place of W6/32 antibody and the nested sets (found for the class II peptides and which are subsets of the identified sequence differing by up to several amino acids at either terminus) were discovered after the source sequence was determined.
- the present invention also relates to these ten class II MHC peptides and their respective nested sets to either stimulate an immune response against the cancer or function as diagnostic markers of the disease.
- the present invention also encompasses any amino acid sequence comprising a peptide sequence selected from the group consisting of GERAMTKDNNLLGKFELT (SEQ ID NO: 5), EGERAMTKDNNLLGKFE (SEQ ID NO: 6), GERAMTKDNNLLGK (SEQ ID NO: 7), ERAMTKDNNLLGKFE (SEQ ID NO: 8), VPGTYKITASARGYNP (SEQ ID NO: 9), VPGTYKITASARGYNPV (SEQ ID NO: 10), PGTYKITASARGYNP (SEQ ID NO: 11), LNQELRADGTVNQIEG (SEQ ID NO: 12), LNQELRADGT NQIEGE (SEQ ID NO: 13), QELRADGTVNQIEG (SEQ ID NO: 14), QELRADGTVNQIEGE
- the invention also encompasses peptide mimetics of the peptides GERAMTKDNNLLGKFELT (SEQ ID NO: 5), EGERAMTKDNNLLGKFE (SEQ ID NO: 6), GERAMTKDNNLLGK (SEQ ID NO: 7), ERAMTKDNNLLGKFE (SEQ ID NO: 8), VPGTYKITASARGYNP (SEQ ID NO: 9), VPGTYKITASARGYNPV (SEQ ID NO: 10), PGTYKITASARGYNP (SEQ ID NO: 11), LNQELRADGTVNQIEG (SEQ ID NO: 12), LNQELRADGTVNQIEGE (SEQ ID NO: 13), QELRADGTVNQIEG (SEQ ID NO: 14), QELRADGTVNQIEGE (SEQ ID NO: 15) TGQFLYQDSNWASK (SEQ ID NO: 16), TGQFLYQDSNWASKVE (SEQ ID NO: 17), NPLEIVSIPDNHGH
- Oligopeptides as disclosed herein may themselves be prepared by methods well known to those skilled in the art. (Grant, G. A., Synthetic
- the proteins and polypeptides forming the immunogens of the present invention may also comprise one or more other immunogenic amino acid stretches known to be associated with cancer, and more specifically with prostate cancer, and which may stimulate a CTL response whereby the immunogenic peptides associate with class I MHC or class 2 MHC molecules, as the case may be.
- oligopeptides and polypeptides useful in practicing the present invention may be derived by fractionation of naturally occurring proteins by methods such as protease treatment, or they may be produced by recombinant or synthetic methodologies that are well known and clear to the skilled artisan (Ausubel, F. M. et al, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, Inc., New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor).
- the polypeptide may comprise a recombinant or synthetic polypeptide that necessarily comprises at least one of SEQ ID NOs:1-31 which sequences may also be present in multiple copies.
- oligopeptides and polypeptides of the present invention may have one, two, three, or more such immunogenic peptides within the amino acid sequence of said oligopeptides and polypeptides, and said immunogenic peptides, or epitopes, may be the same or may be different, or may have any number of such sequences wherein some of them are identical to each other in amino acid sequence while others within the same polypeptide sequence are different from each other and said epitopic sequences may occur in any order within said immunogenic polypeptide sequence.
- immunogens of the present invention may affect relative immunogenic activity.
- immunogens of the present invention may comprise more than one protein comprising the amino acid sequences disclosed herein.
- Such polypeptides may be part of a single composition or may themselves be covalently or non-covalently linked to each other.
- the immunogenic peptides disclosed herein may also be linked directly to, or through a spacer or linker to: an immunogenic carrier such as serum albumin, tetanus toxoid, keyhole limpet hemocyanin, dextran, or a recombinant virus particle; an immunogenic peptide known to stimulate a T helper cell type immune response; a cytokine such as interferon gamma or GMCSF; a targeting agent such as an antibody or receptor ligand; a stabilizing agent such as a lipid; or a conjugate of a plurality of epitopes to a branched lysine core structure, such as the so-called “multiple antigenic peptide" described in (Posnett, D.
- an immunogenic carrier such as serum albumin, tetanus toxoid, keyhole limpet hemocyanin, dextran, or a recombinant virus particle
- Spacers and linkers are typically comprised of relatively small, neutral molecules, such as amino acids and which are substantially uncharged under physiological conditions. Such spacers are typically selected from the group of nonpolar or neutral polar amino acids, such as glycine, alanine, serine and other similar amino acids. Such optional spacers or linkers need not be comprised of the same residues and thus may be either homo- or hetero- oligomers.
- linkers When present, such linkers will commonly be of length at least one or two, commonly 3, 4, 5, 6, and possibly as much as 10 or even up to 20 residues (in the case of amino acids). In addition, such linkers need not be composed of amino acids but any oligomeric structures will do as well so long as they provide the correct spacing so as to optimize the desired level of immunogenic activity of the immunogens of the present invention.
- the immunogen may therefore take any form that is capable of eliciting a CTL response.
- immunogenic peptides of the present invention may be part of an immunogenic structure via attachments other than conventional peptide bonds.
- any manner of attaching the peptides of the invention to an immunogen of the invention could provide an immunogenic structure as claimed herein.
- immunogens, such as proteins of the invention are structures that contain the peptides disclosed according to the present invention but such immunogenic peptides may not necessarily be attached thereto by the conventional means of using ordinary peptide bounds.
- the immunogens of the present invention simply contain such peptides as part of their makeup, but how such peptides are to be combined to form the final immunogen is left to the talent and imagination of the user and is in no way restricted or limited by the disclosure contained herein.
- the peptides may be modified at amino acid residues that are predicted to interact with the class I or class II MHC molecule, in which case the goal is to create a peptide that has a higher affinity for the MHC molecule than does the parent peptide.
- the peptides can also be modified at amino acid residues that are predicted to interact with the T cell receptor on the CTL, in which case the goal is to create a peptide that has a higher affinity for the T cell receptor than does the parent peptide. Both of these types of modifications can result in a variant peptide that is related to a parent peptide, but which is better able to induce a CTL response than is the parent peptide.
- parent peptide means an oligopeptide with the amino acid sequence of SEQ ID NO: 1 -31.
- immunogens according to the invention may be produced using immunogenic peptides disclosed herein but with appropriate substitutions of one or more amino acids to increase the desired immunological effect, such as by conservative substitutions (conservative meaning as defined elsewhere herein) or even non-conservative substitutions.
- substitutions may also involve structures other than the common L-amino acids.
- D-amino acids might be substituted for the L-amino acids commonly found in the antigenic peptides of the invention and yet still be encompassed by the disclosure herein.
- amino acids possessing non-standard R groups i.e., R groups other than those found in the common 20 amino acids of natural proteins may also be used for substitution purposes to produce immunogens and immunogenic polypeptides according to the present invention.
- substitutions at more than one position are found to result in a peptide with substantially equivalent or greater antigenic activity as defined below, then combinations of those substitutions will be tested to determine if the combined substitutions result in additive or syngeneic effects on the antigenicity of the peptide. At most, no more than about 4 or 5 positions within the peptide would simultaneously be substituted.
- an epitope is considered substantially identical to the reference peptide if it has at least 10% of the antigenic activity of the reference peptide as defined by the ability of the substituted peptide to reconstitute the epitope recognized by a CTL in comparison to the reference peptide.
- the observed percent specific killing of the target cells incubated with the substituted peptide should be equal to that of the reference peptide at an effecto ⁇ target ratio that is no greater than 10-fold above the reference peptide effecto ⁇ target ratio at which the comparison is being made.
- the peptide concentration at which the substituted peptides achieve half the maximal increase in lysis relative to background is no more than about 1 mM, preferably no more than about 1 ⁇ M, more preferably no more than about 1 nM, and still more preferably no more than about 100 pM, and most preferably no more than about 10 pM. It is also preferred that the substituted peptide be recognized by CTLs from more than one individual, at least two, and more preferably three individuals.
- the epitopes of the present invention may be identical to naturally occurring tumor-associated or tumor-specific epitopes or may include epitopes that differ by no more than 4 or 5 residues from the reference peptide, as long as they have substantially identical antigenic activity.
- the immunogens of the invention can also comprise a polypeptide that itself comprises one or more of the epitopic peptides of SEQ ID NOS: 1 -31 .
- immunogenic peptides and polypeptides of the invention can be prepared synthetically, by recombinant DNA technology, or they can be isolated from natural sources such as tumor cells expressing the parent protein product.
- polypeptides and oligopeptides disclosed herein can be synthesized in solution or on a solid support in accordance with conventional techniques.
- Various automated peptide synthesizers are commercially available and can be used in accordance with known protocols. See, for example, (Grant, G. A., Synthetic Peptides: A User's Guide, 1992, W. H. Freeman and Company, New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York). Fragments of polypeptides of the invention can also be synthesized as intermediates in the synthesis of a larger polypeptide.
- Recombinant DNA technology may be employed wherein a nucleotide sequence which encodes an immunogenic peptide or polypeptide of interest is inserted into an expression vector, transformed or transfected into an appropriate host cell, and cultivated under conditions suitable for expression.
- These procedures are well known in the art to the skilled artisan, as described in (Coligan, J. E. et al, Current Protocols in Immunology, 1999, John Wiley & Sons, Inc., New York; Ausubel, F. M. et al, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor).
- recombinantly produced peptides or polypeptides can be used as the immunogens of the invention.
- the coding sequences for peptides of the length contemplated herein can be synthesized on commercially available automated DNA synthesizers using protocols that are well know in the art. See for example, (Grant, G. A., Synthetic Peptides: A User's Guide, 1992, W. H. Freeman and Company, New York; Coligan, J. E. et al, Current Protocols in Protein Science, 1999, John Wiley & Sons, Inc., New York).
- the coding sequences can also be modified such that a peptide or polypeptide will be produced that incorporates a desired amino acid substitution.
- the coding sequence can be provided with appropriate linkers, be ligated into suitable expression vectors that are commonly available in the art, and the resulting DNA or RNA molecule can be transformed or transfected into suitable hosts to produce the desired fusion protein.
- suitable host systems are available, and their selection is left to the skilled artisan.
- the coding sequence will be provided with operably linked start and stop codons, promoter and terminator regions, and a replication system to provide an expression vector for expression in the desired host cell.
- promoter sequences compatible with bacterial hosts are provided in plasmids containing convenient restriction sites for insertion of the desired coding sequence.
- the resulting expression vectors are transformed into suitable bacterial hosts.
- yeast, insect, and mammalian host cells may also be used, employing suitable vectors and control sequences.
- Host cells are genetically engineered (transduced or transformed or transfected) with the vectors of this invention which may be, for example, a cloning vector or an expression vector.
- the vector may be, for example, in the form of a plasmid, a viral particle, a phage, etc.
- the engineered host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters, selecting transformants or amplifying the genes of the present invention.
- the culture conditions such as temperature, pH and the like, are those previously used with the host cell selected for expression, and will be apparent to the ordinarily skilled artisan.
- the present invention also includes recombinant constructs comprising one or more of the sequences as broadly described above.
- the constructs comprise a vector, such as a plasmid or viral vector, into which a sequence of the invention has been inserted, in a forward or reverse orientation.
- the construct further comprises regulatory sequences, including, for example, a promoter, operably linked to the sequence.
- a promoter operably linked to the sequence.
- Bacterial pQE70, pQE60, pQE-9 (Qiagen), pBS, pD10, phagescript, ps ⁇ ' X174, pBluescript SK, pBSKS, pNH8A, pNH16a, pNH18A, pNH46A (Stratagene); pTRC99a, pKK223-3, pKK233-3, pDR540, pRIT5 (Pharmacia); Eukaryotic: pWLNEO, pSV2CAT, pOG44, pXT1 , pSG (Stratagene) pSVK3, pBPV, pMSG, pSVL (Pharmacia). However, any other plasmid or vector may be used as long as they are replicable and viable in the host.
- the present invention relates to host cells containing the above-described constructs.
- the host cell can be a higher eukaryotic cell, such as a mammalian cell, or a lower eukaryotic cell, such as a yeast cell, or the host cell can be a prokaryotic cell, such as a bacterial cell.
- Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-Dextran mediated transfection, or electroporation (Ausubel, F. M. et al, Current Protocols in Molecular Biology, 1999, John Wiley & Sons, Inc., New York; Molecular Cloning: A Laboratory Manual, 1989, Cold Spring Harbor Laboratory Press, Cold Spring Harbor).
- Such cells can routinely be utilized for assaying CTL activity by having said genetically engineered, or recombinant, host cells express the immunogenic peptides of the present invention.
- mammalian cell culture systems can also be employed to express recombinant protein.
- mammalian expression systems include the COS-7 lines of monkey kidney fibroblasts, described by Gluzman, Cell, 23:175 (1981 ), and other cell lines capable of expressing a compatible vector, for example, the C127, 3T3, CHO, HeLa and BHK cell lines.
- Mammalian expression vectors will comprise an origin of replication, a suitable promoter and enhancer, and also any necessary ribosome binding sites, polyadenylation site, splice donor and acceptor sites, transcriptional termination sequences, and 5' flanking non-transcribed sequences.
- DNA sequences derived from the SV40 splice, and polyadenylation sites may be used to provide the required nontranscribed genetic elements.
- the polypeptide can be recovered and purified from recombinant cell cultures by methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Protein refolding steps can be used, as necessary, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed for final purification steps.
- HPLC high performance liquid chromatography
- the immunogens of the present invention can be in the form of a composition of one or more of the different immunogens and wherein each immunogen is present in any desired relative abundance.
- Such compositions can be homogeneous or heterogeneous with respect to the individual immunogenic peptide components present therein, having only one or more than one of such peptides.
- compositions of the present invention may thus be formed of any of the immunogens of the invention wherein said composition comprises any of the peptides of the invention, as well as polypeptides or proteins comprising one or more of the peptides disclosed herein, suspended in a pharmaceutically acceptable carrier, such as any pharmaceutically acceptable diluent or excipient.
- a pharmaceutically acceptable carrier such as any pharmaceutically acceptable diluent or excipient.
- Pharmaceutically acceptable carriers include, but are not limited to, liquids such as water, saline, glycerol and ethanol, and the like, including carriers useful in forming sprays for nasal and other respiratory tract delivery or for delivery to the ophthalmic system.
- liquids such as water, saline, glycerol and ethanol, and the like, including carriers useful in forming sprays for nasal and other respiratory tract delivery or for delivery to the ophthalmic system.
- the immunogenic peptides of the present invention may be used to elicit CTLs ex vivo from either healthy individuals or from cancer patients with cancer, such as prostate carcinoma. Such responses are induced by incubating in tissue culture the individual's CTL precursor lymphocytes together with a source of antigen presenting cells and the appropriate immunogenic peptide.
- suitable antigen presenting cells include dendritic cells, macrophages, and activated B cells.
- the peptide at concentrations between 10 and 40 ⁇ g/ml would be pre- incubated with the antigen presenting cells for periods ranging from 1 to 18 hrs. ⁇ 2 -microglobulin (4 ⁇ g/ml) can be added during this time period to enhance binding.
- the antigen presenting cells may also be held at room temperature during the incubation period (Ljunggren, H.-G. et al., Nature, 346:476-480, (1990)) or pretreated with acid (Zeh, H. J., Ill et al., Hum. Immunol., 39:79-86, (1994)) to promote the generation of denatured MHC molecules which can then bind the peptide.
- the precursor CTLs (responders) are then added to the antigen presenting cells to which the immunogenic peptide has bound (stimulators) at responder to stimulator ratios of between 5:1 and 50:1 , and most typically between 10:1 and 20:1 .
- the co-cultivation of the cells is carried out at 37°C in RPMI 1640, 10% fetal bovine serum, 2 mM L-glutamine, and IL-2 (5-20 Units/ml).
- Other cytokines such as IL-1 , IL-7, and IL-12 may also be added to the culture.
- Fresh IL-2-containing media is added to the cultures every 2-4 days, typically by removing one-half the old media and replenishing it with an equal volume of fresh media. After 7-10 days, and every 7-10 days thereafter, the CTL are re-stimulated with antigen presenting cells to which immunogenic peptide has been bound as described above.
- Fresh IL-2-containing media is added to the cells throughout their culture as described above.
- Antigen presenting cells that are to be used to stimulate a CTL response are typically incubated with peptide of an optimal length, most commonly a nonapeptide, that allows for direct binding of the peptide to the MHC molecule, for example, a class I MHC molecule when utilized a peptide of SEQ ID NO: 1 -4, without additional processing.
- peptide of an optimal length most commonly a nonapeptide, that allows for direct binding of the peptide to the MHC molecule, for example, a class I MHC molecule when utilized a peptide of SEQ ID NO: 1 -4, without additional processing.
- oligopeptides and polypeptides are generally ineffective in binding to class I MHC molecules as they are not efficiently processed into an appropriately sized peptide in the extracellular milieu.
- approaches that are known in the art, however, that allow oligopeptides and polypeptides to be exogenously acquired by a cell, which then allows for their subsequent processing and presentation by a class I MHC molecule.
- Such approaches include electroporation of the molecules into the cell (Harding, C. H. Ill,
- oligopeptides and polypeptides that comprise one or more of the peptides of the invention can be provided to antigen presenting cells in such a fashion that they are delivered to the cytoplasm of the cell, and are subsequently processed to allow presentation of the peptides.
- Antigen presenting cells suitable for stimulating an in vitro CTL response that is specific for one or more of the peptides of the invention can also be prepared by introducing polynucleotide vectors encoding the sequences into the cells.
- These polynucleotides can be designed such that they express only a single peptide of the invention, multiple peptides of the invention, or even a plurality of peptides of the invention.
- Such approaches include the introduction of plasmid DNA through particle-mediated gene transfer or electroporation (Tuting, T. et al., J. Immunol., 160:1 139-1 147, (1998)), or the transduction of cells with an adenovirus expressing the polynucleotide of interest (Perez-Diez, A. et al., Cancer Res., 58:5305- 5309, (1998)).
- oligonucleotides that code for one or more of the peptides of the invention can be provided to antigen presenting cells in such a fashion that the peptides associate with MHC molecules and are presented on the surface of the antigen presenting cell, and consequently are available to stimulate a CTL response.
- the stimulator cells used to generate an in vitro CTL response By preparing the stimulator cells used to generate an in vitro CTL response in different ways, it is possible to control the peptide specificity of CTL response.
- the CTLs generated with a particular peptide will necessarily be specific for that peptide.
- CTLs that are generated with a polypeptide or polynucleotide expressing or coding for particular peptides will be limited to specificities that recognize those peptides.
- stimulator cells, and more specifically dendritic cells can be incubated in the presence of the whole protein.
- stimulator cells, and more specifically dendritic cells can be transduced or transfected with RNA or DNA comprising the polynucleotide sequence encoding the protein.
- peptide epitopes that are naturally cleaved out of the protein, and which are generated in addition to peptide epitopes of SEQ ID NOs:1-31 can associate with an appropriate class I or class II MHC molecule.
- the selection of antigen presenting cells and the type of antigen with which to stimulate the CTL, is left to the ordinary skilled artisan.
- the methods of the present invention include a process for inducing a CTL response in vitro that is specific for a tumor cell expressing a peptide as disclosed herein, whereby the method comprises contacting a CTL precursor lymphocyte with an antigen presenting cell that has bound as an immunogen one or more of the peptides disclosed according to the invention.
- the methods of the present invention include a method for inducing a CTL response in vitro that is specific for a tumor cell expressing one or more antigens of the kind disclosed herein, whereby the method comprises contacting a CTL precursor lymphocyte with an antigen presenting cell that has exogenously acquired an immunogenic oligopeptide or polypeptide that comprises one or more of the peptides disclosed according to the invention.
- a yet additional embodiment of the present invention is directed to a process for inducing a CTL response in vitro that is specific for a tumor cell expressing the kind of antigens disclosed herein, comprising contacting a CTL precursor lymphocyte with an antigen presenting cell that is expressing a polynucleotide coding for a polypeptide of the invention and wherein said polynucleotide is operably linked to a promoter.
- CTLs are known to release a variety of cytokines when they are stimulated by an appropriate target cell, such as a tumor cell expressing the relevant class I or class II MHC molecule, and the corresponding peptide.
- cytokines include IFN- ⁇ , TNF ⁇ , and GM-CSF.
- Methodology for measuring both target cell death and cytokine release as a measure of CTL reactivity are given in (Coligan, J. E. et al, Current Protocols in Immunology, 1999, John Wiley & Sons, Inc., New York).
- about 1 x 10 6 to about 1 x 10 12 , more preferably about 1 x 10 8 to about 1 x 10 11 , and even more preferably, about 1 x 10 9 to about 1 x 10 10 peptide-specific CTL are infused.
- Methodology for reinfusing the T cells into a patient are well known and exemplified in U.S. Patent No. 4,844,893 to Honski, et al., and U.S. Patent No. 4,690,915 to Rosenberg.
- the peptide-specific CTL can be purified from the stimulator cells prior to infusion into the patient.
- monoclonal antibodies directed towards the cell surface protein CD8, present on CTL can be used in conjunction with a variety of isolation techniques such as antibody panning, flow cytometric sorting, and magnetic bead separation to purify the peptide-specific CTL away from any remaining non-peptide specific lymphocytes or from the stimulator cells. These methods are well known in the art, and are their selection is left to the skilled artisan. It should be appreciated that generation of peptide-specific CTLs in this manner, obviates the need for stimulating the CTLs in the presence of tumor. Thus, there is no chance of inadvertently reintroducing tumor cells into the patient.
- one embodiment of the present invention relates to a process for treating a subject with a cancer characterized by tumor cells expressing complexes of the antigens as disclosed herein, whereby CTLs produced in vitro according to the present invention are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.
- Another embodiment of the present invention is directed to a process for treating a subject with cancer characterized by tumor cells expressing any class I MHC molecule and an epitope of SEQ ID NO: 1 to 4, or any class II molecule and an epitope of SEQ ID NO: 5 to 31 , whereby the CTLs are produced in vitro and are specific for the epitope or parent protein and are administered in an amount sufficient to destroy the tumor cells through direct lysis or to effect the destruction of the tumor cells indirectly through the elaboration of cytokines.
- the cancer to be treated is preferably a prostate carcinoma.
- the ex vivo generated CTL can be used to identify and isolate the T cell receptor molecules specific for the peptide.
- the genes encoding the alpha and beta chains of the T cell receptor can be cloned into an expression vector system and transferred and expressed in na ⁇ ve T cells from peripheral blood, T cells from lymph nodes, or T lymphocyte progenitor cells from bone marrow. These T cells, which would then be expressing a peptide-specific T cell receptor, would then have anti-tumor reactivity and could be used in adoptive therapy of cancer, and more specifically prostate carcinoma.
- the immunogenic peptides of the present invention are useful as screening and diagnostic agents.
- the immunogenic peptides of the present invention together with modern techniques of gene screening, make it possible to screen patients for the presence of genes encoding such peptides on cells obtained by biopsy of tumors detected in such patients. The results of such screening may help determine the efficacy of proceeding with the regimen of treatment disclosed herein using the immunogens of the present invention.
- the immunogenic peptides disclosed herein, as well as functionally similar homologs thereof, may be used to screen a sample for the presence of CTLs that specifically recognize the corresponding epitopes.
- the lymphocytes to be screened in this assay will normally be obtained from the peripheral blood, but lymphocytes can be obtained from other sources, including lymph nodes, spleen, tumors, and pleural fluid.
- the peptides of the present invention may then be used as a diagnostic tool to evaluate the efficacy of the immunotherapeutic treatments disclosed herein.
- the in vitro generation of CTL as described above would be used to determine if patients are likely to respond to the peptide in vivo.
- the in vitro generation of CTL could be done with samples of lymphocytes obtained from the patient before and after treatment with the peptides. Successful generation of CTL in vivo should then be recognized by a correspondingly easier ability to generate peptide- specific CTL in vitro from lymphocytes obtained following treatment in comparison to those obtained before treatment.
- the oligopeptides of the invention can also be used to prepare class I or class II MHC tetramers that can be used in conjunction with flow cytometry to quantitate the frequency of peptide-specific CTLs that are present in a sample of lymphocytes from an individual.
- class I MHC molecules and peptides of SEQ ID NO:1 , 2, 3, or 4 would be combined to form tetramers as exemplified in U.S. Patent 5,635,363.
- Said tetramers would find use in monitoring the frequency of CTLs specific for the combination of MHC and a peptide of SEQ ID NO:1 in the peripheral blood, lymph nodes, or tumor mass of an individual undergoing immunotherapy with the peptides, proteins, or polynucleotides of the invention, and it would be expected that successful immunization would lead to an increase in the frequency of the peptide- specific CTL.
- Said tetramers could also be developed for peptides of SEQ ID NOs:5-31 in combination with the appropriate MHC molecule.
- a vaccine in accordance with the present invention may include one or more of the hereinabove described polypeptides or active fragments thereof, or a composition, or pool, of immunogenic peptides disclosed herein.
- more than one polypeptide or active fragment such as two or more polypeptides and/or active fragments may be used as a physical mixture or as a fusion of two or more polypeptides or active fragments.
- the fusion fragment or fusion polypeptide may be produced, for example, by recombinant techniques or by the use of appropriate linkers for fusing previously prepared polypeptides or active fragments.
- the immunogenic molecules of the invention may be utilized according to the present invention for purposes of preventing, suppressing or treating diseases causing the expression of the immunogenic peptides disclosed herein, such as where the antigen is being expressed by tumor cells.
- prevention relates to a process of prophylaxis in which an animal, especially a mammal, and most especially a human, is exposed to an immunogen of the present invention prior to the induction or onset of the disease process. This could be done where an individual has a genetic pedigree indicating a predisposition toward occurrence of the disease condition to be prevented.
- the immunogen could be administered to the general population as is frequently done for infectious diseases.
- the term "suppression” is often used to describe a condition wherein the disease process has already begun but obvious symptoms of said condition have yet to be realized.
- the cells of an individual may have become cancerous but no outside signs of the disease have yet been clinically recognized.
- the term prophylaxis can be applied to encompass both prevention and suppression.
- the term "treatment” is often utilized to mean the clinical application of agents to combat an already existing condition whose clinical presentation has already been realized in a patient. This would occur where an individual has already been diagnosed as having a tumor.
- the suitable dosage of an immunogen of the present invention will depend upon the age, sex, health, and weight of the recipient, the kind of concurrent treatment, if any, the frequency of treatment, and the nature of the effect desired. However, the most preferred dosage can be tailored to the individual subject, as determined by the researcher or clinician.
- the total dose required for any given treatment will commonly be determined with respect to a standard reference dose as set by a manufacturer, such as is commonly done with vaccines, such dose being administered either in a single treatment or in a series of doses, the success of which will depend on the production of a desired immunological result (i.e., successful production of a CTL- mediated response to the antigen, which response gives rise to the prevention and/or treatment desired).
- the overall administration schedule must be considered in determining the success of a course of treatment and not whether a single dose, given in isolation, would or would not produce the desired immunologically therapeutic result or effect.
- the therapeutically effective amount of a composition containing one or more of the immunogens of this invention is an amount sufficient to induce an effective CTL response to the antigen and to cure or arrest disease progression.
- this dose will depend, among other things, on the identity of the immunogens used, the nature of the disease condition, the severity of the disease condition, the extent of any need to prevent such a condition where it has not already been detected, the manner of administration dictated by the situation requiring such administration, the weight and state of health of the individual receiving such administration, and the sound judgment of the clinician or researcher.
- effective amounts would generally lie within the range of from 1 .0 ⁇ g to about 5,000 ⁇ g of peptide for a 70 kg patient, followed by boosting dosages of from about 1 .0 ⁇ g to about 1 ,000 ⁇ g of peptide pursuant to a boosting regimen over days, weeks or even months, depending on the recipient's response and as necessitated by subsequent monitoring of CTL-mediated activity within the bloodstream.
- dosages are to be considered only a general guide and, in a given situation, may greatly exceed such suggested dosage regimens where the clinician believes that the recipient's condition warrants more a aggressive administration schedule.
- the efficacy of administering additional doses, and of increasing or decreasing the interval may be re-evaluated on a continuing basis, in view of the recipient's immunocompetence (for example, the level of CTL activity with respect to tumor-associated or tumor-specific antigens).
- the immunogenic compositions according to the present invention may be used against a disease condition such as cancer by administration to an individual by a variety of routes.
- the composition may be administered parenterally or orally, and, if parenterally, either systemically or topically.
- Parenteral routes include subcutaneous, intravenous, intradermal, intramuscular, intraperitoneal, intranasal, transdermal, or buccal routes. One or more such routes may be employed.
- Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time.
- vaccines are prepared as injectables, in the form of aqueous solutions or suspensions.
- Vaccines in an oil base are also well known such as for inhaling.
- Solid forms which are dissolved or suspended prior to use may also be formulated.
- Pharmaceutical carriers, diluents and excipients are generally added that are compatible with the active ingredients and acceptable for pharmaceutical use. Examples of such carriers include, but are not limited to, water, saline solutions, dextrose, or glycerol. Combinations of carriers may also be used. These compositions may be sterilized by conventional, well known sterilization techniques including sterile filtration.
- Vaccine compositions may further incorporate additional substances to stabilize pH, or to function as adjuvants, wetting agents, or emulsifying agents, which can serve to improve the effectiveness of the vaccine.
- the concentration of the CTL stimulatory peptides of the invention in pharmaceutical formulations are subject to wide variation, including anywhere from less than 0.01 % by weight to as much as 50% or more. Factors such as volume and viscosity of the resulting composition must also be considered.
- the solvents, or diluents, used for such compositions include water, possibly PBS (phosphate buffered saline), or saline itself, or other possible carriers or excipients.
- the immunogens of the present invention may also be contained in artificially created structures such as liposomes, ISCOMS, slow-releasing particles, and other vehicles which increase the immunogenicity and/or half-life of the peptides or polypeptides in serum.
- Liposomes include emulsions, foams, micelies, insoluble monolayers, liquid crystals, phospholipid dispersions, lamellar layers and the like.
- Liposomes for use in the invention are formed from standard vesicle-forming lipids which generally include neutral and negatively charged phospholipids and a sterol, such as cholesterol. The selection of lipids is generally determined by considerations such as liposome size and stability in the blood.
- Liposomes containing the peptides or polypeptides of the invention can be directed to the site of lymphoid cells where the liposomes then deliver the selected immunogens directly to antigen presenting cells.
- Targeting can be achieved by incorporating additional molecules such as proteins or polysaccharides into the outer membranes of said structures, thus resulting in the delivery of the structures to particular areas of the body, or to particular cells within a given organ or tissue.
- Such targeting molecules may a molecule that binds to receptor on antigen presenting cells.
- an antibody that binds to CD80 could be used to direct liposomes to dendritic cells.
- the immunogens of the present invention may also be administered as solid compositions.
- Conventional nontoxic solid carriers including pharmaceutical grades of mannitol, lactose, starch, magnesium, cellulose, glucose, sucrose, sodium saccharin, and the like.
- Such solid compositions will often be administered orally, whereby a pharmaceutically acceptable nontoxic composition is formed by incorporating the peptides and polypeptides of the invention with any of the carriers listed above.
- such compositions will contain 10 - 95% active ingredient, and more preferably 25 - 75% active ingredient.
- Aerosol administration is also an alternative, requiring only that the immunogens be properly dispersed within the aerosol propellant.
- Typical percentages of the peptides or polypeptides of the invention are 0.01 % - 20% by weight, preferably 1 % - 10%.
- the use of a surfactant to properly disperse the immunogen may be required.
- Representative surfactants include the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms, such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride.
- esters such as mixed or natural glycerides may be employed.
- the surfactant may constitute 0.1 - 20% by weight of the composition, preferably 0.25 - 5%.
- Typical propellants for such administration may include esters and similar chemicals but are by no means limited to these.
- a carrier, such as lecithin for intranasal delivery, may also be included.
- the peptides and polypeptides of the invention may also be delivered with an adjuvant.
- Adjuvants include, but are not limited to complete or incomplete Freund's adjuvant, Montanide ISA-51 , aluminum phosphate, aluminum hydroxide, alum, and saponin.
- Adjuvant effects can also be obtained by injecting a variety of cytokines along with the immunogens of the invention. These cytokines include, but are not limited to IL-1 , IL-2, IL-7, IL-12, and GM-CSF.
- the peptides and polypeptides of the invention can also be added to professional antigen presenting cells such as dendritic cells that have been prepared ex vivo.
- the dendritic cells could be prepared from CD34 positive stem cells from the bone marrow, or they could be prepared from CD 14 positive monocytes obtained from the peripheral blood.
- the dendritic cells are generated ex vivo using cytokines such as GM-CSF, IL-3, IL-4, TNF, and SCF.
- the cultured DC are then pulsed with peptides at various concentrations using standard methods that are well known in the art.
- the peptide-pulsed dendritic cells can then be administered either intraveneously, subcutaneously, or intradermally , and the immunization may also include cytokines such as IL-2 or IL-12.
- the present invention is also directed to a vaccine in which an immunogen of the present invention is delivered or administered in the form of a polynucleotide encoding the a polypeptide or active fragment as disclosed herein, whereby the peptide or polypeptide or active fragment is produced in vivo.
- the polynucleotide may be included in a suitable expression vector and combined with a pharmaceutically acceptable carrier.
- the peptides or polypeptides could be expressed in plasmid DNA and nonreplicative viral vectors such as vaccinia, fowlpox, Venezuelan equine encephalitis virus, adenovirus, or other RNA or DNA viruses.
- compositions containing the immunogens disclosed herein may, in addition, contain other antitumor pharmaceuticals.
- the use of such compositions with multiple active ingredients is left to the discretion of the clinician.
- the immunogens of the present invention can be used to stimulate the production of antibodies for use in passive immunotherapy, for use as diagnostic reagents, and for use as reagents in other processes such as affinity chromatography.
- a further embodiment of the present invention relates to a process for inducing a CTL response in a subject comprising administering to subjects that express an immunogen of the invention that do not comprise the entire protein expressing the epitopic peptides disclosed herein in an amount sufficient to induce a CTL response to said tumor cells.
- a still further embodiment of the present invention relates to a method for inducing a CTL response in a subject, wherein the immunogen is in the form of a polynucleotide, and wherein the epitope or epitopes of said immunogen are selected from a group comprising the peptides disclosed according to the invention, and are coded within a polynucleotide sequence that does not comprise the entire protein coding region, in an amount sufficient to induce a CTL response to tumor cells expressing such antigenic sites.
- the present invention also relates to a process for inducing a CTL response in a subject, said process comprising administering at least one immunogen as disclosed herein, including combinations thereof, to a mammal, preferably a human being, found to be over-expressing an epitope of SEQ ID NO: 1 - 31 , or over-expressing a protein or polypeptide comprising such epitope, including any of the immunogens disclosed herein, and in an amount sufficient to induce a CTL response to tumor cells expressing said epitope.
- TYGEIFEKF (SEQ ID NO: 2) GEFGGFGSV (SEQ ID NO: 3)
- EGERAMTKDNNLLGKFE SEQ ID NO: 6
- GERAMTKDNNLLGK SEQ ID NO: 7
- ERAMTKDNNLLGKFE SEQ ID NO: 8
- VPGTYKITASARGYNP SEQ ID NO: 9
- VPGTYKITASARGYNPV SEQ ID NO: 10
- IDLPEYQGEPDEISIQK (SEQ ID NO: 21 IPSVFIGESSANSLKDE (SEQ ID NO: 22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21221300P | 2000-06-16 | 2000-06-16 | |
US21216500P | 2000-06-16 | 2000-06-16 | |
US212165P | 2000-06-16 | ||
US212213P | 2000-06-16 | ||
PCT/US2001/019207 WO2001097827A1 (en) | 2000-06-16 | 2001-06-15 | Mhc peptides over-expressed on prostate cancer cells and methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1303287A1 true EP1303287A1 (de) | 2003-04-23 |
EP1303287A4 EP1303287A4 (de) | 2006-02-08 |
Family
ID=26906839
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01942207A Withdrawn EP1303287A4 (de) | 2000-06-16 | 2001-06-15 | In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1303287A4 (de) |
AU (1) | AU2001275490A1 (de) |
WO (1) | WO2001097827A1 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE385503T1 (de) * | 1999-06-28 | 2008-02-15 | Inter K Pty Ltd | Verfahren zur modulierung von integrin- vermittelter zellaktivitaet und hierfuer geeignete reagenzien |
AUPR230500A0 (en) | 2000-12-22 | 2001-01-25 | University Of Newcastle Research Associates Limited, The | A method of modulating map kinase mediated cellular activity and agents useful in same |
US20100233176A1 (en) * | 2008-10-06 | 2010-09-16 | Cashman Neil R | Methods and systems for predicting misfolded protein epitopes |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998033888A1 (en) * | 1997-01-31 | 1998-08-06 | Epimmune, Inc. | Peptides and peptide-loaded antigen presenting cells for the activation of ctl |
US5846810A (en) * | 1994-10-28 | 1998-12-08 | Kyowa Hakko Kogyo Co. Ltd. | Human 26S proteasome subunit components |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1990002564A1 (en) * | 1988-09-12 | 1990-03-22 | Codon | Vaccine diagnostic employing proteins homologous to heat shock proteins of trypanosoma cruzi |
-
2001
- 2001-06-15 WO PCT/US2001/019207 patent/WO2001097827A1/en not_active Application Discontinuation
- 2001-06-15 AU AU2001275490A patent/AU2001275490A1/en not_active Abandoned
- 2001-06-15 EP EP01942207A patent/EP1303287A4/de not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5846810A (en) * | 1994-10-28 | 1998-12-08 | Kyowa Hakko Kogyo Co. Ltd. | Human 26S proteasome subunit components |
WO1998033888A1 (en) * | 1997-01-31 | 1998-08-06 | Epimmune, Inc. | Peptides and peptide-loaded antigen presenting cells for the activation of ctl |
Non-Patent Citations (4)
Title |
---|
CORREALE P ET AL: "Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide" JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 161, 1998, pages 3186-3194, XP002975760 ISSN: 0022-1767 * |
SCHMIDT WALTER ET AL: "Cell-free tumor antigen peptide-based cancer vaccines" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 7, 1997, pages 3262-3267, XP002168512 ISSN: 0027-8424 * |
See also references of WO0197827A1 * |
TJOA B A ET AL: "PROGRESS IN ACTIVE SPECIFIC IMMUNOTHERAPY OF PROSTATE CANCER" SEMINARS IN SURGICAL ONCOLOGY, vol. 18, no. 1, 2000, pages 80-87, XP000915524 ISSN: 8756-0437 * |
Also Published As
Publication number | Publication date |
---|---|
WO2001097827A1 (en) | 2001-12-27 |
EP1303287A4 (de) | 2006-02-08 |
AU2001275490A1 (en) | 2002-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9907842B2 (en) | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer | |
US20080107668A1 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
WO2007150077A2 (en) | Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
WO2009036246A2 (en) | Immunogens that induce cytotoxic t-lymphocytes and their use in prevention, treatment, and diagnosis of cancer | |
US7083789B2 (en) | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer | |
KR20230142704A (ko) | 암 면역요법을 위한 조직 특이적 항원 | |
US20020137683A1 (en) | C-ski oncogene-derived peptides for prevention, treatment, and diagnosis of cancer | |
EP1303287A1 (de) | In prostata-krebszellen überexprimierte mhc-peptide und methoden zu deren verwendung | |
US10206990B2 (en) | Cytotoxic T lymphocyte inducing immunogens for prevention treatment and diagnosis of cancer | |
US20030211116A1 (en) | Mhc peptides over-expressed on prostate cancer cells and methods of use | |
US20020192229A1 (en) | MHC class I associated peptides for prevention and treatment of tuberculosis | |
JP2002527109A (ja) | 腫瘍抗原lage−1の選択的翻訳産物、camel | |
FLYER et al. | Patent 2430896 Summary | |
WO2001032193A1 (en) | Cytotoxic t lymphocyte-stimulating peptides for prevention, treatment, and diagnosis of melanoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030116 |
|
AK | Designated contracting states |
Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7C 07K 14/47 B Ipc: 7C 12N 5/08 B Ipc: 7C 12N 5/06 B Ipc: 7C 07K 16/00 B Ipc: 7C 07K 7/00 B Ipc: 7A 01N 63/00 B Ipc: 7A 61K 39/00 B Ipc: 7A 61K 39/395 B Ipc: 7A 61K 38/04 B Ipc: 7A 61K 38/00 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20051223 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20060715 |